Literature DB >> 17239369

Persistence of tolerance to methamphetamine-induced monoamine deficits.

Jonathan P Danaceau1, Cassandra E Deering, Jayme E Day, Stacy J Smeal, Kamisha L Johnson-Davis, Annette E Fleckenstein, Diana G Wilkins.   

Abstract

Methamphetamine is a highly addictive and potent stimulant, the use of which has increased significantly in recent years. In addition to the severe behavioral and societal consequences associated with methamphetamine abuse, methamphetamine can cause persistent damage to monoaminergic nerve terminals in rats, as measured by either monoamine concentrations or activity of the rate limiting synthetic enzymes, tyrosine hydroxylase and tryptophan hydroxylase. Repeated, sub-neurotoxic doses of methamphetamine, however, can cause rats to become resistant to the neurotoxic effects of multiple high-dose administrations of methamphetamine; a phenomenon known as tolerance. This study investigates the persistence of tolerance evoked by pretreatment with escalating-dose administrations of methamphetamine. Rats were pretreated over several days with low, escalating doses of methamphetamine, followed by high-dose methamphetamine challenge after variable recovery periods. Results revealed that tolerance to monoaminergic deficits persisted for at least one week, but was completely eliminated by 31 days. There were no differences in the distribution of methamphetamine or its major metabolite, amphetamine, between methamphetamine-pretreated animals and saline-pretreated animals 2 h after the final methamphetamine challenge injection, and there were no regional differences in methamphetamine concentrations between the frontal cortex, hippocampus or striatum. We also observed that while methamphetamine pretreatment attenuated the hyperthermia caused by the high-dose methamphetamine challenge, significant reductions in methamphetamine-induced hyperthermia were not required for the development of tolerance with this regimen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17239369     DOI: 10.1016/j.ejphar.2006.11.045

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  32 in total

1.  Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.

Authors:  Lisa M McFadden; Madison M Hunt; Paula L Vieira-Brock; Janice Muehle; Shannon M Nielsen; Scott C Allen; Glen R Hanson; Annette E Fleckenstein
Journal:  Drug Alcohol Depend       Date:  2012-05-28       Impact factor: 4.492

Review 2.  Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways.

Authors:  Irina N Krasnova; Zuzana Justinova; Jean Lud Cadet
Journal:  Psychopharmacology (Berl)       Date:  2016-02-12       Impact factor: 4.530

Review 3.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

4.  Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2015-01-31       Impact factor: 5.250

5.  Methamphetamine preconditioning causes differential changes in striatal transcriptional responses to large doses of the drug.

Authors:  Jean Lud Cadet; Christie Brannock; Bruce Ladenheim; Michael T McCoy; Genevieve Beauvais; Amber B Hodges; Elin Lehrmann; William H Wood; Kevin G Becker; Irina N Krasnova
Journal:  Dose Response       Date:  2010-07-02       Impact factor: 2.658

6.  Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration.

Authors:  Goran Laćan; Martin Hadamitzky; Ronald Kuczenski; William P Melega
Journal:  Synapse       Date:  2013-03-19       Impact factor: 2.562

7.  Effects of DDIT4 in Methamphetamine-Induced Autophagy and Apoptosis in Dopaminergic Neurons.

Authors:  Bing Li; Rui Chen; Ling Chen; Pingming Qiu; Xiuyun Ai; Enping Huang; Weiye Huang; Chuanxiang Chen; Chao Liu; Zhoumeng Lin; Wei-Bing Xie; Huijun Wang
Journal:  Mol Neurobiol       Date:  2016-02-12       Impact factor: 5.590

8.  Methamphetamine preconditioning: differential protective effects on monoaminergic systems in the rat brain.

Authors:  Jean Lud Cadet; Irina N Krasnova; Bruce Ladenheim; Ning-Sheng Cai; Michael T McCoy; Fidelis E Atianjoh
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

9.  Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.

Authors:  Jarom E Hanson; Elisabeth Birdsall; Kristi S Seferian; Marcus A Crosby; Kristen A Keefe; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2009-04-01       Impact factor: 4.432

10.  Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum.

Authors:  Jean Lud Cadet; Michael T McCoy; Ning Sheng Cai; Irina N Krasnova; Bruce Ladenheim; Genevieve Beauvais; Natascha Wilson; William Wood; Kevin G Becker; Amber B Hodges
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.